These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7735216)

  • 1. Molecular parameters for the anti-human immunodeficiency virus activity of T22 ([Tyr5,12, Lys7]-polyphemusin II).
    Otaka A; Tamamura H; Terakawa Y; Masuda M; Koide T; Murakami T; Nakashima H; Matsuzaki K; Miyajima K; Ibuka T
    Biol Pharm Bull; 1994 Dec; 17(12):1669-72. PubMed ID: 7735216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of an anti-HIV peptide, T22.
    Tamamura H; Murakami T; Masuda M; Otaka A; Takada W; Ibuka T; Nakashima H; Waki M; Matsumoto A; Yamamoto N
    Biochem Biophys Res Commun; 1994 Dec; 205(3):1729-35. PubMed ID: 7811258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).
    Tamamura H; Arakaki R; Funakoshi H; Imai M; Otaka A; Ibuka T; Nakashima H; Murakami T; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Bioorg Med Chem; 1998 Feb; 6(2):231-8. PubMed ID: 9547946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.
    Tamamura H; Waki M; Imai M; Otaka A; Ibuka T; Waki K; Miyamoto K; Matsumoto A; Murakami T; Nakashima H; Yamamoto N; Fujii N
    Bioorg Med Chem; 1998 Apr; 6(4):473-9. PubMed ID: 9597190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
    Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The synthetic [Tyr5,12,Lys7]-polyphemusin II peptide (T22) binds to the CD4 cell surface molecule.
    Weeks BS; Nomizu M; Otaka A; Weston CA; Okusu A; Tamamura H; Yamamoto N; Fujii N
    Biochem Biophys Res Commun; 1995 Oct; 215(2):626-31. PubMed ID: 7488001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of an anti-HIV peptide, T22, with gp120 and CD4.
    Tamamura H; Otaka A; Murakami T; Ishihara T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Biochem Biophys Res Commun; 1996 Feb; 219(2):555-9. PubMed ID: 8605026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II).
    Masuda M; Nakashima H; Ueda T; Naba H; Ikoma R; Otaka A; Terakawa Y; Tamamura H; Ibuka T; Murakami T
    Biochem Biophys Res Commun; 1992 Dec; 189(2):845-50. PubMed ID: 1472056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance.
    Tamamura H; Kuroda M; Masuda M; Otaka A; Funakoshi S; Nakashima H; Yamamoto N; Waki M; Matsumoto A; Lancelin JM
    Biochim Biophys Acta; 1993 May; 1163(2):209-16. PubMed ID: 8490053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion.
    Nakashima H; Masuda M; Murakami T; Koyanagi Y; Matsumoto A; Fujii N; Yamamoto N
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1249-55. PubMed ID: 1384424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance.
    Tamamura H; Ishihara T; Otaka A; Murakami T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Biochim Biophys Acta; 1996 Nov; 1298(1):37-44. PubMed ID: 8948487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
    Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
    AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocytes and promonocytes attach to the synthetic [Tyr5,12, Lys7]- polyphemusin II peptide.
    Weeks BS; Nomizu M; Otaka A; Weston CA; Okusu A; Tamamura H; Matsumoto A; Yamamoto N; Fujii N
    Biochem Biophys Res Commun; 1994 Jul; 202(1):470-5. PubMed ID: 8037749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solution-phase synthesis of an anti-human immunodeficiency virus peptide, T22 ([Tyr5,12,Lys7]-polyphemusin II), and the modification of Trp by the p-methoxybenzyl group of Cys during trimethylsilyl trifluoromethanesulfonate deprotection.
    Tamamura H; Otaka A; Takada W; Terakawa Y; Yoshizawa H; Masuda M; Ibuka T; Murakami T; Nakashima H; Waki M
    Chem Pharm Bull (Tokyo); 1995 Jan; 43(1):12-8. PubMed ID: 7895303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
    Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
    Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-HIV peptide, T22, forms a highly active complex with Zn(II).
    Tamamura H; Otaka A; Murakami T; Ibuka T; Sakano K; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Biochem Biophys Res Commun; 1996 Dec; 229(2):648-52. PubMed ID: 8954952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
    Murakami T; Nakajima T; Koyanagi Y; Tachibana K; Fujii N; Tamamura H; Yoshida N; Waki M; Matsumoto A; Yoshie O; Kishimoto T; Yamamoto N; Nagasawa T
    J Exp Med; 1997 Oct; 186(8):1389-93. PubMed ID: 9334379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
    Tamamura H; Omagari A; Oishi S; Kanamoto T; Yamamoto N; Peiper SC; Nakashima H; Otaka A; Fujii N
    Bioorg Med Chem Lett; 2000 Dec; 10(23):2633-7. PubMed ID: 11128640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A synthetic peptide "T22" as anti-HIV agents].
    Nakashima H; Murakami T
    Nihon Rinsho; 1993 Sep; 51 Suppl():146-52. PubMed ID: 8271378
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
    Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
    Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.